{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T05:24:49Z","timestamp":1772774689720,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","award":["GZ-2017-11748"],"award-info":[{"award-number":["GZ-2017-11748"]}],"id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.clgc.2022.04.009","type":"journal-article","created":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T23:57:57Z","timestamp":1650931077000},"page":"496.e1-496.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-World Cabazitaxel Use and Outcomes in Metastatic Castrate-Resistant Prostate Cancer: The Impact of Response to First ARPI"],"prefix":"10.1016","volume":"20","author":[{"given":"Alexander S","family":"Watson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Gagnon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugene","family":"Batuyong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nimira","family":"Alimohamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Lee-Ying","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2022.04.009_bib0001","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2022.04.009_bib0002","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.eururo.2014.02.056","article-title":"Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)","volume":"66","author":"Rathkopf","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2022.04.009_bib0003","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"New England J Med"},{"key":"10.1016\/j.clgc.2022.04.009_bib0004","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"New England J Med"},{"key":"10.1016\/j.clgc.2022.04.009_bib0005","doi-asserted-by":"crossref","unstructured":"Fizazi K, Scher HI, Molina A, et\u00a0al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13:983-992. doi:10.1016\/S1470-2045(12)70379-0","DOI":"10.1016\/S1470-2045(12)70379-0"},{"key":"10.1016\/j.clgc.2022.04.009_bib0006","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"New England J Med"},{"key":"10.1016\/j.clgc.2022.04.009_bib0007","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2022.04.009_bib0008","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2022.04.009_bib0009","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2022.04.009_bib0010","article-title":"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer","volume":"0","author":"Sartor","year":"2021","journal-title":"New England J Med"},{"issue":"24","key":"10.1016\/j.clgc.2022.04.009_bib0011","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with olaparib in metastatic castration-resistant prostate cancer","volume":"383","author":"Hussain","year":"2020","journal-title":"New England J Med"},{"issue":"25","key":"10.1016\/j.clgc.2022.04.009_bib0012","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.2217\/fon-2019-0190","article-title":"Sequencing strategies in the new treatment landscape of prostate cancer","volume":"15","author":"Caffo","year":"2019","journal-title":"Future Oncology"},{"key":"10.1016\/j.clgc.2022.04.009_bib0013","doi-asserted-by":"crossref","DOI":"10.1038\/s41391-021-00344-1","article-title":"The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world population","author":"Westgeest","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.clgc.2022.04.009_bib0014","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","article-title":"Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer","volume":"381","author":"de Wit","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2022.04.009_bib0015","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1016\/S1470-2045(19)30688-6","article-title":"Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial","volume":"20","author":"Khalaf","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2022.04.009_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102152","article-title":"Optimal treatment sequencing of abiraterone acetate plus prednisone and enzalutamide in patients with castration-resistant metastatic prostate cancer: a systematic review and meta-analysis","volume":"93","author":"Cassinello","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clgc.2022.04.009_bib0017","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.eururo.2014.11.033","article-title":"Targeting the androgen receptor confers in vivo cross-resistance between enzalutamide and docetaxel, but not cabazitaxel, in castration-resistant prostate cancer","volume":"67","author":"van Soest","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2022.04.009_bib0018","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.eururo.2014.06.045","article-title":"Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients","volume":"67","author":"Azad","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2022.04.009_bib0019","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1093\/annonc\/mdt138","article-title":"Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide","volume":"24","author":"Noonan","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2022.04.009_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2018.08.002","volume":"36","author":"Oh","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2022.04.009_bib0021","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.eururo.2014.04.015","article-title":"Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies","volume":"68","author":"Al Nakouzi","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2022.04.009_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2021.03.205","article-title":"Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2 trial","author":"Annala","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2022.04.009_bib0023","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s41416-019-0611-6","article-title":"Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort","volume":"121","author":"Rouyer","year":"2019","journal-title":"Br J Cancer"},{"issue":"7_suppl","key":"10.1016\/j.clgc.2022.04.009_bib0024","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1200\/JCO.2019.37.7_suppl.256","article-title":"Treatment patterns and outcomes for metastatic castration-resistant prostate cancer (mCRPC) in a real-world setting: a retrospective study of greater than 2500 patients","volume":"37","author":"Higano","year":"2019","journal-title":"JCO"},{"key":"10.1016\/j.clgc.2022.04.009_bib0025","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2022.04.009_bib0026","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.6_suppl.TPS387","article-title":"A randomized phase II study comparing cabazitaxel\/prednisone to cabazitaxel alone for second-line chemotherapy in men with metastatic castrate resistant prostate cancer (mCRPC): CABACARE","volume":"36","author":"Buonerba","year":"2018","journal-title":"JCO"},{"key":"10.1016\/j.clgc.2022.04.009_bib0027","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"New Engl J Med"},{"key":"10.1016\/j.clgc.2022.04.009_bib0028","doi-asserted-by":"crossref","first-page":"111084","DOI":"10.18632\/oncotarget.22560","article-title":"Integrative molecular network analysis identifies emergent enzalutamide resistance mechanisms in prostate cancer","volume":"8","author":"King","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.clgc.2022.04.009_bib0029","doi-asserted-by":"crossref","first-page":"21750","DOI":"10.1038\/s41598-020-78798-x","article-title":"Enzalutamide response in a panel of prostate cancer cell lines reveals a role for glucocorticoid receptor in enzalutamide resistant disease","volume":"10","author":"Smith","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.clgc.2022.04.009_bib0030","doi-asserted-by":"crossref","first-page":"12315","DOI":"10.1073\/pnas.1922207117","article-title":"Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance","volume":"117","author":"Alumkal","year":"2020","journal-title":"PNAS"},{"key":"10.1016\/j.clgc.2022.04.009_bib0031","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41585-020-0289-9","article-title":"Does sequencing order of antiandrogens in prostate cancer matter?","volume":"17","author":"Maughan","year":"2020","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.clgc.2022.04.009_bib0032","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.eururo.2018.01.035","article-title":"Germline DNA-repair gene mutations and outcomes in men with metastatic castration-resistant prostate cancer receiving first-line abiraterone and enzalutamide","volume":"74","author":"Antonarakis","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2022.04.009_bib0033","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1038\/s41598-017-04897-x","article-title":"Mutations in BRCA2 and taxane resistance in prostate cancer","volume":"7","author":"Nientiedt","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.clgc.2022.04.009_bib0034","doi-asserted-by":"crossref","first-page":"106468","DOI":"10.18632\/oncotarget.22474","article-title":"Prognostic factors in men with metastatic castration-resistant prostate cancer treated with cabazitaxel","volume":"8","author":"Belderbos","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.clgc.2022.04.009_bib0035","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.2147\/PPA.S106629","article-title":"Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature","volume":"10","author":"Eek","year":"2016","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.clgc.2022.04.009_bib0036","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10549-005-3376-y","article-title":"Perception that oral anticancer treatments are less efficacious: development of a questionnaire to assess the possible prejudices of patients with cancer","volume":"92","author":"Catania","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clgc.2022.04.009_bib0037","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1001\/jama.2020.6236","article-title":"Oncology practice during the COVID-19 pandemic","volume":"323","author":"Schrag","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.clgc.2022.04.009_bib0038","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1200\/JCO.2016.72.1076","article-title":"Phase III study comparing a reduced dose of cabazitaxel (20 mg\/m2) and the currently approved dose (25 mg\/m2) in postdocetaxel patients with metastatic castration-resistant prostate cancer-PROSELICA","volume":"35","author":"Eisenberger","year":"2017","journal-title":"J Clin Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767322000866?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767322000866?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:35:21Z","timestamp":1761564921000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767322000866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S1558767322000866"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2022.04.009","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Cabazitaxel Use and Outcomes in Metastatic Castrate-Resistant Prostate Cancer: The Impact of Response to First ARPI","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2022.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}